These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

142 related items for PubMed ID: 11303390

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. [Treatment with chimeric monoclonal antitumor necrosis factor (infliximab) of patients with active steroid-dependent/resistant Crohn's disease and fistulas].
    Martorana G, Casà A, Oliva L, Orlando A, Cottone M.
    Recenti Prog Med; 2001; 92(7-8):451-5. PubMed ID: 11475786
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. [Treatment of Crohn's disease with anti-TNF alpha antibodies (infliximab): results of a multicentric and retrospective study].
    Doubremelle M, Bourreille A, Zerbib F, Heresbach D, Metman EH, Beau P, Gournay J, Galmiche JP.
    Gastroenterol Clin Biol; 2002 Nov; 26(11):973-9. PubMed ID: 12483127
    [Abstract] [Full Text] [Related]

  • 10. Infliximab in the surgical management of complex fistulating anal Crohn's disease.
    Talbot C, Sagar PM, Johnston MJ, Finan PJ, Burke D.
    Colorectal Dis; 2005 Mar; 7(2):164-8. PubMed ID: 15720356
    [Abstract] [Full Text] [Related]

  • 11. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease.
    Baert F, Noman M, Vermeire S, Van Assche G, D' Haens G, Carbonez A, Rutgeerts P.
    N Engl J Med; 2003 Feb 13; 348(7):601-8. PubMed ID: 12584368
    [Abstract] [Full Text] [Related]

  • 12. Clinical experience with infliximab therapy in 100 patients with Crohn's disease.
    Farrell RJ, Shah SA, Lodhavia PJ, Alsahli M, Falchuk KR, Michetti P, Peppercorn MA.
    Am J Gastroenterol; 2000 Dec 13; 95(12):3490-7. PubMed ID: 11151882
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Infliximab for the treatment of Crohn's disease: efficacy, safety and pharmacoeconomics.
    Feagan BG, Enns R, Fedorak RN, Panaccione R, Paré P, Steinhart AH, Wild G.
    Can J Clin Pharmacol; 2001 Dec 13; 8(4):188-98. PubMed ID: 11743591
    [Abstract] [Full Text] [Related]

  • 15. Fistulating anal Crohn's disease: results of combined surgical and infliximab treatment.
    Hyder SA, Travis SP, Jewell DP, McC Mortensen NJ, George BD.
    Dis Colon Rectum; 2006 Dec 13; 49(12):1837-41. PubMed ID: 17041753
    [Abstract] [Full Text] [Related]

  • 16. Infliximab for Crohn's disease in clinical practice: the experience of a single center in romania.
    Gheorghe L, Gheorghe C, Badea M, Vădan R, Pârvulescu I, Toader C, Tugui L, Papuc O, Ionescu R, Preda C, Călin I, Diculescu M.
    Rom J Gastroenterol; 2003 Mar 13; 12(1):7-13. PubMed ID: 12673373
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Anti-interleukin-12 antibody for active Crohn's disease.
    Mannon PJ, Fuss IJ, Mayer L, Elson CO, Sandborn WJ, Present D, Dolin B, Goodman N, Groden C, Hornung RL, Quezado M, Yang Z, Neurath MF, Salfeld J, Veldman GM, Schwertschlag U, Strober W, Anti-IL-12 Crohn's Disease Study Group.
    N Engl J Med; 2004 Nov 11; 351(20):2069-79. PubMed ID: 15537905
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.